Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component

Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component.

This is a monocentric, prospective, randomized clinical survey to verify if the periprosthetic remodelling brought about either the AMIStem or the Quadra femoral component is equivalent.

Inclusion Criteria:

• Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to the patient's surgery.
• Patients presenting with disease that meets the indications for use for Medacta implants defined by this study (on-label use (enclosure 2)).
• Patients must be willing to comply with the pre and post-operative evaluation schedule.
• Patients with only one lower limb arthroplasty

Exclusion Criteria:

• Patient with metabolic bone diseases, use of steroids or other drugs affecting bone metabolism
• Patients with osteoporosis (pre-op T-score < -2,5)
• Patients with significant comorbidities
• Patients with both hip and knee arthroplasty
• Patients with restricted mobility
• Patient with severe hip contracture
• Those with one or more medical conditions identified as a contraindication defined by the labeling on any Medacta implants used in this study